Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Inclusion Criteria:

For Roll-over Subjects Only:

• Met the criteria as a Study Completer in one of three studies (DMVT-505-3101 study,DMVT-505-3102 study, or DMVT-505-2104 study).

• Must not be pregnant at Baseline

For Direct-Enrolling Subjects Only:

• Male and female subjects ages 2 years to < 18 years at the time of consent withclinical diagnosis of AD

• Subjects with a vIGA-AD™ score of ≥ 3 and AD covering ≥ 40% of the BSA at Screeningand Baseline (pre-randomization), or subjects with a vIGA-AD™ score of 2 atScreening and Baseline (pre-randomization) regardless of BSA. Subjects must havescreened for the DMVT-505-3101 or DMVT-505-3102 study and failed to meet BSA and/orvIGA-AD™ eligibility criteria.

• AD present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old

• Must not be pregnant at Screening or Baseline

For All Subjects:

• Female subjects of childbearing potential who are engaging in sexual activity thatcould lead to pregnancy should use acceptable birth control methods

• Subject, subject's parent, or legal representative must be capable of giving writteninformed consent/assent

Exclusion Criteria:

For Rollover Subjects Only:

1. Subjects who were not receiving study drug at the time of the last visit in thepivotal study (DMVT-505-3101, DMVT-505-3102, or DMVT-505-2104)

2. Used a prohibited concomitant product or procedure to treat AD during the pivotalstudy.

3. Had an SAE that was related to treatment or experienced an AE that led to permanentdiscontinuation of treatment in the pivotal study.

4. Pregnant females

For Direct-Enrolling Subjects:

• Immunocompromised at screening

• Chronic or acute systemic or superficial infection requiring treatment with systemicantibacterials or antifungals within one week prior to baseline visit

• Significant dermatological or inflammatory condition other than AD that, in theInvestigator's opinion, would make it difficult to interpret data or assessmentsduring the study

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upperlimit of normal (ULN).

• Screening total bilirubin > 1.5x ULN

• Current or chronic history of liver disease

• Current or history of cancer within 5 years except for adequately treated cutaneousbasal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix

• Subjects who would not be considered suitable for topical therapy

• Use of any prohibited medication or procedure within the indicated period before thebaseline visit including other investigational product within 30 days or 5half-lives of the investigational product (whichever is longer)

• History of or ongoing serious illness or medical, physical, or psychiatriccondition(s) that, in the Investigator's opinion, may interfere with the subject'sparticipation in the study, interpretation of results, or ability to understand andgive informed consent.

• Pregnant or lactating females

• History of sensitivity to the study medications, or components thereof or a historyof drug or other allergy that, in the opinion of the Investigator or MedicalMonitor, contraindicates their participation

• Previous known participation in a clinical study with tapinarof (previously known asGSK2894512 and WBI-1001)